Primary Aldosteronism Foundation Announces Alliance to Help Diagnose and Treat Common Causes of Hypertension

PHOENIX, September 28, 2022 /PRNewswire/ — The Primary Aldosteronism Foundation (“Foundation”) today announced the formation of a multi-stakeholder alliance to advance the diagnosis and treatment of primary aldosteronism, a common cause of hypertension. Among the partners is Mineralys Therapeutics, Inc, a biopharmaceutical company developing a new therapy for the treatment of hypertension.

The initiative will facilitate the design and implementation of interventions to advance standards of care for primary aldosteronism, a widespread adrenal disease and a common cause of hypertension. Primary aldosteronism is neither diagnosed nor treated in 95% of cases, despite significant cardiovascular and renal damage as well as systemic inflammation.

“The Alliance was formed to highlight the unmet medical needs of millions of patients,” said Marianne Leenaerts, co-founder and co-director of the Foundation. “For the first time since the disease was discovered more than 60 years ago, collaborative work will lead to action to address this major public health issue by addressing the factors that prevent the delivery of timely care. and adequately.

This critical step precedes a long-awaited paradigm shift in the medical treatment of primary aldosteronism with the advent of aldosterone synthase inhibitors, a new class of drugs that, for the very first time, will reduce aldosterone .

“We are pleased to partner with the Foundation to raise awareness of the diagnosis, treatment and management of aldosterone-induced disorders such as primary aldosteronism,” said Jon Congleton, CEO of Mineralys Therapeutics. “Abnormal aldosterone levels are a common cause of hypertension, making it an important imperative. Together with the Foundation, we hope to meet standards of care for hypertension and primary aldosteroneism and support its commitment to hypertension prescribers, patients and caregivers.”

Founding members of the Alliance include American medical societies and stakeholders involved in healthcare delivery, clinical research and public health. There was consensus to begin work focusing on primary and specialty care, advancing the research agenda and improving current guidelines. The initiative aims to grow its membership across the healthcare sector through 2023 and beyond.

About the Primary Aldosteronism Foundation
A 501(c)(3) tax-exempt charitable organization, the Primary Aldosteronism Foundation is headquartered in Phoenix, AZ. The organization is dedicated to advancing standards of care for patients by:

  • Design and implement interventions with healthcare stakeholders and industry leaders to address patients’ unmet medical needs;
  • Promote innovative ways to reach those who are undiagnosed and include their lived experiences in care and research processes;
  • Advocacy for research funding proportional to the number of patients concerned with the aim of filling the knowledge gap on excess aldosterone and translating this knowledge into diagnostic and therapeutic solutions.

About Mineralys Therapeutics, Inc.
Based at Philadelphia, Pennsylvania, Mineralys Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company engaged in the development of novel, cutting-edge therapy for the treatment of hypertension. The company is committed to bringing a targeted approach to the management of hypertension through the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being studied for the treatment of hypertension. For more information, please visit https://mineralystx.com/.

Contact:
Marianne Leenaerts
Foundation of primary aldosteronism
Phone: +1 (602) 726-0665
E-mail: [email protected]

SOURCE Primary Aldosteronism Foundation

Comments are closed.